Advertisement

BLFS

BioLife Solutions Inc

Healthcare · USD

Set alert

Price alert · BLFS

All alert types
38.61 USD 0.00 0.00%
As of Oct 5, 2026 Extended hours 28.10 -27.22%
Bid
28.64 × 2
Ask
28.66 × 2
36.96 Day range 38.83
17.86 52-week range 39.76
YTD
0.00%
1 year
0.00%
Open
0.00
Prev close
38.61
Mkt cap
1.89B
Vol
0
Avg vol
1.16M
EPS
0.99
P/E
39.00
Div yield
0.00%
More statistics
Low
36.96
High
38.83
Forward P/E
117.00
Beta
1.82
Short ratio
4.54
Inst. own
105.51%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
36.08
200-d avg
26.77
1y target
31.00

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for BLFS has not been loaded yet. Try again in a moment.

Key statistics

Market cap
1.89B
Enterprise value
1.82B
Trailing P/E
39.00
Forward P/E
117.00
PEG ratio
15.09
Price / sales
17.71
Price / book
4.49
EPS (TTM)
0.99
Beta
1.82
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
54.35%
Revenue (TTM)
106.69M
Revenue growth
21.50%
Free cash flow
4.66M
Total cash
82.42M
Total debt
15.74M
Return on equity
12.83%
Shares outstanding
48.92M
Short % of float
10.82%
50-day average
36.08
200-day average
26.77

Analyst view

Consensus: hold

Hold
Price target (mean) 31.00
Ratings (0m) 6 0 buy · 6 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold6
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate 0.07.

Earnings history

Financials — quick view

All financials
BLFS Revenue — quarterly 28.47M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BLFS Net income — quarterly 45.10M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BLFS EPS — quarterly 0.92
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

BLFS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 20260.05———
Aug 6, 2026Jun 30, 20260.031250.91+0.88+2,812.00%
May 7, 2026Mar 31, 20260.010.04+0.03+300.00%
Feb 26, 2026Dec 31, 2025-0.020.04+0.06+300.00%
Nov 6, 2025Sep 30, 20250.0020.04+0.04+1,900.00%
Aug 7, 2025Jun 30, 2025-0.02-0.33-0.31-1,550.00%

Upgrades / downgrades

BLFS analyst upgrades and downgrades
DateFirmActionFromTo
Aug 10, 2026BenchmarkdownBuyHold
Jul 27, 2026Stephens & Co.downOverweightEqual-Weight
Jul 23, 2026JefferiesdownBuyHold
Jul 23, 2026TD CowendownBuyHold
Jul 22, 2026Lake StreetdownBuyHold
Jul 22, 2026HC Wainwright & Co.downBuyNeutral

About BioLife Solutions Inc

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States

News

Your note

Sign in to keep a note on BLFS — it syncs with the Stock Master app.

Insider holders

BLFS insider holders
InsiderRelationLatest transactionDateShares held
AEBERSOLD SARAHOfficerSaleMar 2, 202693,360
BERARD TODD C.J.OfficerSaleMar 2, 2026165,940
CASDIN PARTNERS MASTER FUND, L.P.Beneficial Owner of more than 10% of a Class of SecuritySaleOct 14, 20250
DE GREEF RODERICKChief Executive OfficerStock Award(Grant)Feb 23, 2026744,847
ELLINGSON RACHEL H.DirectorStock Award(Grant)Feb 23, 202657,995
FOSTER KAREN AOfficerSaleMar 22, 2026108,758

Institution ownership

BLFS institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.13.80%6,751,135260.66MJun 29, 2026
Blackrock Inc.13.03%6,375,545246.16MJun 29, 2026
Casdin Capital, LLC9.51%4,655,000179.73MJun 29, 2026
Invesco Ltd.4.58%2,240,42386.50MJun 29, 2026
Vanguard Capital Management LLC4.01%1,964,08475.83MJun 29, 2026
State Street Corporation3.38%1,655,92763.94MJun 29, 2026

Fund ownership

BLFS fund ownership
Holder% heldSharesValueReported
T. Rowe Price Small-Cap Stock Fund, Inc.5.17%2,527,32597.58MJun 29, 2026
iShares Trust-iShares Core S&P Small-Cap ETF4.93%2,410,57493.07MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%1,461,21256.42MJun 29, 2026
T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd.2.82%1,378,71853.23MJun 29, 2026
TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust2.43%1,188,59645.89MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.21%1,079,08141.66MAug 30, 2026
Advertisement